IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference
IRLAB announced today that Dr. Susanna Holm Waters, director of Biology and Biostatistics at IRLAB, will be presenting a poster titled “Preclinical pharmacology of IRL752, a novel compound to treat postural instability and cognitive deficits in Parkinson’s disease” at the Society for Neuroscience (SfN) 2019 Neuroscience conference. The conference will take place on October 19-23 at the McCormick Place Convention Center in Chicago, US.
The international SfN Neuroscience conference is the largest gathering of researchers and healthcare professionals working in the field of neuroscience with the goal of advancing breakthrough discoveries in the field of neuroscience. Each year, the conference attracts 30,000 leading neuroscientists sharing their newest research results and present emerging science among peers. The 2019 conference also marks the 50th anniversary of Society for Neuroscience.
Clas Sonesson, CSO at IRLAB, commented “The SfN Neuroscience conference is the most impactful conference for neuroscientists across the globe. It’s important for IRLAB to be present at these types of congresses to show and discuss our research within the medical community. Not only does the audience consist of leading experts and researchers in the field but also some of the key pharmaceutical companies in the world.”
Find the poster presentation at the congress:
Presentation time: Wednesday, October 23 at 09:00 – 10:00
Presentation number: 653.18
Abstract title: Preclinical pharmacology of IRL752, a novel compound to treat postural instability and cognitive deficits in Parkinson’s disease
Session title: Genetic models of Parkinson’s disease
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
IRLAB is a Swedish biotech company focused on Parkinson's disease. The company's clinical Phase II candidates, IRL752 and IRL790, intend to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (LIDs), psychosis and dementia. Through the proprietary ISP (Integrative Screening Process) research platform, IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where big growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, email@example.com, +46 (0)8‑528 00 399. More information on www.irlab.se.